Clinical trials: Cannabidiol
Infantile Spasms
Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)
This trial consists of 3 parts: a pilot safety phase, a pivotal randomized controlled phase, and an open-label extension phase. The pilot phase only will be described in this record.
- Trial name
- NCT02953548
- Testing
- GWP42003-P
- Where
- 8 sites in United States, Poland
- Volunteers
- 9 people
- Sponsor
- Jazz Pharmaceuticals
Autism Spectrum Disorder
Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder
This study will be conducted to evaluate the efficacy of GWP42003-P, compared with placebo, in reducing symptom severity in children with Autism Spectrum Disorder (ASD).
- Trial name
- NCT04745026
- Testing
- GWP42003-P
- Where
- 23 sites in United States, Australia and 4 more
- Volunteers
- 103 people
- Sponsor
- Jazz Pharmaceuticals
Dravet Syndrome, Lennox Gastaut Syndrome
A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking Cannabidiol
This is an open label study to evaluate the safety of ZX008 (fenfluramine) in patients with Dravet syndrome (DS) or Lennox Gastaut syndrome (LGS) who are being administered cannabidiol (CBD).
- Trial name
- NCT03467113
- Testing
- ZX008 0.2 to 0.8 mg/kg/day, Cannabidiol
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Prevention aGVHD
An Open Label Study of Multiple Doses of Cannabidiol in the Prevention of Acute Graft-Versus-Host Disease (GVHD)
A prospective, open-label, phase 2a study, to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of multiple doses of Cannabidiol (CBD) in participants Graft-Versus-Host Disease (GVHD) after allogeneic hematopoietic…
- Trial name
- NCT03840512
- Testing
- CBD
- Where
- 5 sites in Australia, Israel
- Volunteers
- 36 people
- Sponsor
- Kalytera Therapeutics Israel, Ltd.
PK in Healthy Volunteers
Pharmacokinetic Study of a Novel Cannabidiol (CBD) Formulation in Healthy Volunteers
The purpose of this study is to test a new formulation of cannabidiol (CBD) to see how it is processed in the body and how safe it is for healthy volunteers.
- Trial name
- NCT07186283
- Testing
- CBD soft-gel capsules 600 mg, CBD soft-gel capsules 900 mg, Epidyolex
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- NW PharmaTech Ltd
Lennox-Gastaut Syndrome
A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS
This is a Phase 3b/Phase 4 study. The purpose of this study is to learn more about the efficacy of using CBD-OS as an add-on therapy for the treatment of LGS in adults.
- Trial name
- EpiGOAL (NCT07728097)
- Testing
- Cannabidiol Oral Solution
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jazz Pharmaceuticals
Sleep Disturbance, Insomnia
The CANabidiol Use for RElief of Short Term Insomnia
This study aims to investigate the effect of 50 mg and 100 mg per day oral CBD product versus a placebo over 8 weeks on insomnia severity in adults aged 18-65 years old with insomnia symptoms.
- Conditions
- Sleep Disturbance, Insomnia, Insomnia Type; Sleep Disorder, Insomnia, Transient
- Trial name
- CANREST (NCT05253417)
- Testing
- 50 mg Cannabidiol (CBD), 100 mg Cannabidiol (CBD)
- Where
- 2 sites in Australia
- Volunteers
- 208 people
- Sponsor
- Bod Australia
Coronary Heart Disease, Dyslipidemias
A Study of Atorvo+™ in Healthy Adult Participants
A Phase 1 study will assess the safety, tolerability, and pharmacokinetics of Atorvo+™ in healthy adult participants. .
- Trial name
- NCT06615284
- Testing
- Atorvo+™ (Arm1), Atorvo+™ +CBD (Arm 2), Atorvo+™ +CBD (Arm 3)
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Indication Bioscience LLC
Social Anxiety Disorder
CHI-902 for Treatment of Social Anxiety Disorder
No substantial clinical trials of Cannabidiol (CBD) in Social Anxiety Disorder (SAD) have yet been conducted. This randomized doubleblind, placebo-controlled trial of CBD in adults with SAD will evaluate the efficacy…
- Trial name
- NCT04086342
- Testing
- CHI-902
- Where
- 2 sites in Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Canopy Growth Corporation
Fragile X Syndrome, Fragile X Syndrome (FXS)
Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome
This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of cannabidiol administered as ZYN002 for the treatment of children, adolescent, and young adult patients with…
- Trial name
- RECONNECT (NCT04977986)
- Testing
- ZYN002
- Where
- 27 sites in United States, Australia and 3 more
- Volunteers
- 257 people
- Sponsor
- Harmony Biosciences Management, Inc.
Cosmetic Acne
Effect of a Facial Cream Containing Cannabidiol and Hemp Oil on Skin Hydration and Acne-prone Skin
This research seeks to evaluate the short (i.e., after single application) and long-term (i.e., after periodic application) hydrating effect of a topical preparation containing CBD and hemp oil on facial skin as well as the…
- Trial name
- Dahlia (NCT04045119)
- Testing
- Topical Moisturizer
- Where
- Colombia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Avicanna Inc
Epilepsy, Dravet Syndrome
An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Adults With Dravet or Lennox-Gastaut Syndromes
To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and adults with Dravet or Lennox-Gastaut syndromes.
- Conditions
- Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
- Trial name
- GWPCARE5 (NCT02224573)
- Testing
- GWP42003-P
- Volunteers
- 681 people
- Sponsor
- GW Research Ltd
Maternal Complications, Pregnancy Complication
Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy
The purpose of this study is to evaluate pregnancy-related health outcomes in participants who are exposed to Epidiolex/Epidyolex during pregnancy and their infant up to 12 months of life.
- Conditions
- Maternal Complications, Pregnancy Complication, Birth Outcomes, Adverse, Pregnancy
- Trial name
- NCT06113237
- Testing
- Epidiolex
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 50 people
- Sponsor
- Jazz Pharmaceuticals
Musculoskeletal Pain
Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain
The purpose of the study is to evaluate whether Pure Green tablets is a better pain reliever for the treatment of mild to moderate musculoskeletal pain.
- Trial name
- NCT04193631
- Testing
- Cannabidiol (CBD)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Pure Green
Hepatic Impairment
Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients
A Phase I open-label study to evaluate the pharmacokinetics (what the body does to a drug), safety and tolerability of a single dose of Sativex (containing 10.8 mg tetrahydrocannabinol [THC] and 10 mg cannabidiol [CBD]) in…
- Trial name
- NCT01887301
- Testing
- Sativex
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jazz Pharmaceuticals
CBD Pharmacokinetics, Healthy Participants
A Pharmacokinetic Study to Compare CBD-NE to Epidyolex in Healthy Adult Volunteers Under Both Fed and Fasted Conditions
Cannabidiol (CBD), derived from the Cannabis sativa plant, is being investigated for its potential health benefit without the psychoactive properties and adverse reactions that arise from the use of delta-9-tetrahydrocannabinol…
- Trial name
- NCT06578455
- Testing
- Cannabidiol (CBD) Powder, Cannabidiol 100 MG/ML [Epidiolex]
- Where
- Canada
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG
Dysmenorrhea, Headache, Migraine
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
Sublingual Tablets With Cannabinoid Combinations for the Treatment of Dysmenorrhea
- Conditions
- Dysmenorrhea, Headache, Migraine, Fatigue, Nausea
- Trial name
- NCT04091789
- Testing
- Pure Femme Tablets
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pure Green
Cosmetics; Eczema
Effect of an Emollient Cream Containing 0.5% Cannabidiol and 1% Hemp Oil in the Hydration and Erythema of the Skin
This research seeks to evaluate the short (i.e., after single application) and long-term (i.e., after periodic application) hydrating effect of a topical preparation containing CBD and hemp oil on the skin of the volar forearm as…
- Trial name
- Celosia (NCT04045314)
- Testing
- Topical moisturizer
- Where
- Colombia
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Avicanna Inc
Atopic Dermatitis
Comparison of JW-100 and EUCRISA for the Treatment of Atopic Dermatitis
To compare the efficacy of a JW-100 cream with active control (commercially available as EUCRISA®, Pfizer) for the treatment of atopic dermatitis (AD) in adult patients with mild to moderate AD measured with the Investigator's…
- Trial name
- NCT05016284
- Testing
- JW-100, Eucrisa
- Where
- Brazil
- Sponsor
- Applied Biology, Inc.
Epilepsy
A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The blinded phase only will be described in this record.
- Trial name
- NCT02565108
- Testing
- GWP42003-P 20 mg/kg/Day Dose, Clobazam
- Where
- 6 sites in Spain, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Jazz Pharmaceuticals